Date: 2016-02-23
Type of information: Private placement
Company: Oxford Biomedica (UK)
Investors:
Amount:
Funding type: private placement
Planned used: The principal purpose of the Placing is to provide adequate working capital for the Group to continue to fund its investment in the Group’s product development pipeline and in the development of lentiviral vector manufacturing-related technology to enable it to take advantage of a number of important catalysts expected during 2016.
Others: * On February 23, 2016, Oxford BioMedica announced that it intends to raise £8.1 million pursuant to a placing of 128,383,528 new ordinary shares in the Company at a price of 6.3 pence per Placing Share with both new and existing investors together with the Directors. The Offer Price of 6.3 pence per Placing Share represents a 10.0 per cent. discount to the closing price of 7.0 pence per ordinary share in the Company on 22 February 2016 (being the last trading day prior to the date of this announcement). Jefferies International is acting as Sponsor, Global Co-Ordinator and Bookrunner for the Company and WG Partners is acting as UK Placement Agent for the Company in connection with the Placing.
Therapeutic area:
